It was only 2014 when investigators first noted that the PCP subtype carried the BRAF V600E mutation, which has paved the way for further diagnostic testing as well as targeted immunotherapy treatments that are undergoing current assessment. The gene discussed is BRAF; the disease is pneumocystosis.